Introduction

CAS Number: 9039-53-6
Standard: In-House/IP/EP/BP standard

Urokinase remains an important tool in the management of thrombotic disorders, providing life-saving interventions for patients experiencing severe thrombosis-related problems.

Applications

Urokinase, is an enzyme extracted from human urine and is a type of fibrinolytic enzyme. Its primary function is to promote the dissolution of blood clots and is widely used in the treatment of thrombotic diseases.

Uses:

Acute Myocardial Infarction (AMI) Treatment:

Urokinase can be used in thrombolytic therapy for acute myocardial infarction to help dissolve blood clots obstructing coronary arteries and restore blood flow.

Pulmonary Embolism (PE) Treatment:

It is used in patients with acute pulmonary embolism to help dissolve blood clots blocking pulmonary blood vessels.

Deep Vein Thrombosis (DVT) Treatment:

Urokinase is used for patients with deep vein thrombosis to prevent the further extension of the clot and reduce complications.

Catheter-Related Thrombosis:

In some cases, urokinase can be used to dissolve thrombi caused by catheters, ensuring catheter patency.

Other Fibrinolytic Treatments:

It is used in the treatment of certain types of thrombotic diseases, such as cerebral thrombosis, etc.

Advantages:

Effective Thrombolysis: Urokinase activates the fibrinolytic system directly, rapidly dissolving blood clots, restoring blood flow, and reducing ischemic damage.

Relative Safety: Compared to other thrombolytic agents (such as streptokinase), urokinase has a lower risk of bleeding, making it suitable for certain patient populations.

Lower Immune Response: Since urokinase is derived from human urine, its immunogenicity is relatively low, reducing the likelihood of allergic reactions in patients.

Flexible Administration: Urokinase can be administered via intravenous injection or catheter-based delivery, allowing for flexible adjustment based on the patient's condition.

Thrombolytic Therapy for High-Risk Conditions: Urokinase is crucial in saving lives in emergency situations, such as acute myocardial infarction, pulmonary embolism, and other critical thrombotic diseases.

Overall, urokinase has become an essential drug in the treatment of acute thrombotic conditions due to its thrombolytic effectiveness and relatively low side effects. However, its use still requires close monitoring of patients for bleeding risks and other complications.